Efficient induction method of human astrocytes

By culturing a mixed cell population of nerve cells and astrocyte precursors under suitable conditions, using ROCK inhibitors and specific culture media to rapidly isolate and amplify astrocyte precursors, the prior art is solved The problem of long differentiation time has achieved efficient and high-purity astrocyte induction, which is suitable for drug development and disease treatment.

CN119040264APending Publication Date: 2024-11-29CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310618418.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the prior art, the differentiation process of astrocytes takes a long time and it is difficult to obtain functional cells, and an efficient induction method is urgently needed.

Method used

By culturing a mixed cell population of nerve cells and astrocyte precursors under suitable conditions, using ROCK inhibitors and specific culture media, the rapid isolation and amplification of astrocyte precursors can be achieved, thereby obtaining high purity astrocytes.

Benefits of technology

It achieves rapid and efficient induction of astrocytes, shortens the differentiation time, and obtains high-purity astrocytes, with proliferation and directional differentiation capabilities, and is suitable for drug development and disease treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004255136800000011
    Figure HDA0004255136800000011
  • Figure HDA0004255136800000021
    Figure HDA0004255136800000021
  • Figure HDA0004255136800000031
    Figure HDA0004255136800000031
Patent Text Reader

Abstract

The invention discloses an efficient induction method of human astrocytes. The human astrocytes comprise astrocytes at the front end of a human brain and human spinal cord astrocytes. Specifically, the method provided by the invention relates to a method for differentiating human pluripotent stem cells (hPSCs) into human astrocyte precursors through human neural precursor cells, and further efficiently and directionally differentiating the human astrocyte precursors into the astrocyte population. According to the method for culturing the astrocytes, the mature astrocytes with good quality and high purity can be quickly and easily obtained.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of neurobiology, and in particular to a highly efficient induction method for human astrocytes. Background Art

[0002] Human pluripotent stem cells (hPSCs) include human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), which provide unprecedented opportunities for scientific progress, biomedical research and drug development. hESCs and hiPSCs can continuously self-renew and have the potential to differentiate into the three germ layers. Therefore, these human pluripotent stem cells are considered as a possible means to treat degenerative, malignant, genetic diseases or injuries caused by inflammation, infection and trauma. At the same time, hESCs and hiPSCs are valuable research tools to study and simulate early human development (normal and abnormal) and understand basic biological issues such as cell proliferation, differentiation and cell plasticity. In addition, they can serve as a platform for developing and testing new drugs. In order to fully realize the potential of hESCs and hiPSCs, the most critical step is to efficiently differentiate pluripotent stem cells into cell types of specific lineages.

[0003] In the prior art, astrocytes are usually obtained by inducing differentiation from human pluripotent stem cells into astrocytes, and the process cycle is often long. For example, there are many methods for inducing differentiation of astrocytes from iPSC in vitro (Emdadet al., 2012; Juopperi et al., 2012; Krencik and Ullian, 2013; Roybon et al., 2013; Shaltouki et al., 2013), which are often time-consuming and difficult to obtain functional astrocytes. Zhang et al. found that there are two distinct states of astrocytes in the brain: one is a proliferative astrocyte precursor state, and the other is a non-proliferative, mature astrocyte (Zhang et al., 2016). Pasca's team used brain organoid technology to establish brain organoids from human pluripotent stem cells. After 590 days of long-term differentiation, it was found that astrocytes have a transition from proliferation to maturity (Solan et al., 2017). Differentiating astrocytes from neural progenitor cells is a relatively time-saving method. In the reported methods, the time is about 30 days (TCW et al., 2017). The above methods for in vitro differentiation of astrocytes are characterized by being time-consuming.

[0004] Therefore, there is an urgent need in the art to develop an efficient method for inducing human astrocytes. Summary of the invention

[0005] The purpose of the present invention is to provide a highly efficient method for inducing human astrocytes.

[0006] In a first aspect of the present invention, there is provided a method for preparing a mixed cell population of neural cells and astrocyte precursors, comprising the steps of:

[0007] (1) providing a precursor cell; and

[0008] (2) culturing the precursor cells in the coated culture medium for a period of time T1 under conditions suitable for differentiation of the precursor cells into neural cells and astrocyte precursors, thereby obtaining a mixed cell population containing neural cells and astrocyte precursors, wherein the culture period T1 is 8-30 days,

[0009] In a mixed cell population containing neurons and astrocyte precursors, the proportion of neurons in the total number of cells is C1, and the proportion of astrocyte precursors in the total number of cells is C2, wherein C1:C2=(70%-98%):(1%-10%).

[0010] In another preferred embodiment, the precursor cells can differentiate into neural cell and astrocyte precursors; preferably human neural cell and human astrocyte precursors.

[0011] In another preferred embodiment, the precursor cells are derived from human pluripotent stem cells (hPSC), human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC), and neural stem cells (NSC).

[0012] In another preferred embodiment, the precursor cells are derived from induced neural stem cells (iNSC).

[0013] In another preferred embodiment, the precursor cells are human neural precursor cells, such as human spinal cord neural precursor cells.

[0014] In another preferred embodiment, in (2), the conditions suitable for the differentiation of human neural progenitor cells into neural cells and astrocyte precursors include: culturing in the presence of a ROCK inhibitor.

[0015] In another preferred embodiment, in (2), the conditions suitable for differentiating human neural progenitor cells into neural cell and astrocyte precursors include: culturing human neural progenitor cells in a culture system containing a first culture medium containing 6-12 μM ROCK inhibitor.

[0016] In another preferred embodiment, the first culture medium is: N2B27 culture medium without Vitamin A.

[0017] In another preferred embodiment, the coated culture medium is a cell culture plate coated with Matrigel.

[0018] In another preferred embodiment, the ROCK inhibitor is Y27632.

[0019] In another preferred embodiment, the seeding density of human neural precursor cells is 1×10 3 -2×10 5 / cm 2 , preferably 5×10 3 -8×10 4 / cm 2 ; preferably 1×10 4 -2×10 4 / cm 2 .

[0020] In another preferred embodiment, in (2), the culture time T1 is 10-25 days, more preferably 12-20 days.

[0021] In another preferred embodiment, in (2), in the mixed cell population containing neurons and astrocyte precursors, the proportion of neurons in the total number of cells is C1, and the proportion of astrocyte precursors in the total number of cells is C2, wherein C1:C2 = (40%-95%): (2%-18%); more preferably C1:C2 = (30%-90%): (3%-30%).

[0022] In a second aspect of the present invention, a method for culturing astrocyte precursors is provided, comprising the steps of:

[0023] (1) providing a mixed cell population containing neural cells and astrocyte precursors;

[0024] (2) digesting the mixed cell population in (1) to obtain a digested mixed cell population, wherein the digested mixed cell population comprises a single neural cell and a single astrocyte precursor in a suspended state;

[0025] (3) inoculating the digested mixed cell population in an uncoated culture medium in a culture system of a second culture medium, and adhering to the culture medium for a t2 time, so that the astrocyte precursors adhere to the culture medium, wherein t2 is 10-24 hours;

[0026] (4) separating the adherent astrocyte precursors from the suspended cells in the culture system, and washing the adherent astrocyte precursors in the culture medium to remove the residual suspended cells, thereby obtaining separated adherent astrocyte precursors, wherein the astrocyte precursors account for 70-95% of the total number of cells; and

[0027] (5) The adherent astrocyte precursors separated in the previous step are expanded and cultured to obtain human astrocyte precursors that are stably and continuously passaged.

[0028] In another preferred embodiment, the mixed cell population containing neural cells and astrocyte precursors is prepared by the method of the first aspect of the present invention.

[0029] In another preferred embodiment, the uncoated culture medium is an uncoated cell culture dish or culture bottle.

[0030] In another preferred embodiment, in (1), the density of the mixed cell population is 1×10 4 -2×10 7 cells / cm 2 .

[0031] In another preferred embodiment, in (2), the digestion treatment includes adding a cell digestion solution (such as Accutase) and digesting at 37 degrees for 3-10 minutes.

[0032] In another preferred embodiment, in (3), the inoculation density of the digested mixed cell population is 1×10 5 -1×10 6 cells / mL.

[0033] In another preferred embodiment, the second culture medium is N2B27 culture medium without Vitamin A.

[0034] In another preferred embodiment, the second culture medium does not contain transdifferentiation overexpressed transcription factors (such as NF1A).

[0035] In another preferred embodiment, the t2 is 11-20h, more preferably 12h.

[0036] In another preferred embodiment, in (4), the isolated adherent astrocyte precursors have one or more characteristics selected from the following group:

[0037] More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene S100β;

[0038] More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene NFIA.

[0039] In another preferred embodiment, (5) comprises the steps of:

[0040] Digest the isolated adherent astrocyte precursors obtained in the above step and centrifuge at 10,000-50,000 / cm 2 The cells were seeded in a culture dish coated with Matrigel at a density of and subcultured in the third culture medium to obtain stable and continuously passaged human astrocyte precursors.

[0041] In another preferred embodiment, the third culture medium is N2B27 culture medium without Vitamin A, which contains 5-25 ng / mL EGF and 5-25 ng / mL bFGF, more preferably, 10-20 ng / mL EGF and 10-20 ng / mL bFGF.

[0042] In another preferred embodiment, in (5), the subculture is at least 10 generations, preferably at least 20 generations, and more preferably at least 30-40 generations.

[0043] In a third aspect of the present invention, there is provided a method for isolating astrocyte precursors from a mixed cell population containing neural cells and astrocyte precursors, comprising the steps of:

[0044] (1) providing a mixed cell population containing neural cells and astrocyte precursors;

[0045] (2) digesting the mixed cell population in (1) to obtain a digested mixed cell population, wherein the digested mixed cell population comprises a single neural cell and a single astrocyte precursor in a suspended state;

[0046] (3) inoculating the digested mixed cell population in an uncoated culture medium in a culture system of a second culture medium, and culturing the cells for a t2 period of time, so that the astrocyte precursors adhere to the culture medium, wherein t2 is 10-24 hours; and

[0047] (4) Separating the adherent astrocyte precursors from the suspended cells in the culture system, and washing the adherent astrocyte precursors in the culture medium to remove the residual suspended cells, thereby obtaining separated adherent astrocyte precursors, wherein the astrocyte precursors account for 70-95% of the total number of cells.

[0048] In a fourth aspect of the present invention, an astrocyte precursor is provided, wherein the astrocyte precursor is prepared by the following method:

[0049] (1) Providing a precursor cell;

[0050] (2) culturing human neural progenitor cells in a culture system containing a first culture medium containing 6-12 μM ROCK inhibitor, and culturing in the coated culture medium for a period of time T1, thereby obtaining a mixed cell population containing neural cell and astrocyte precursors, wherein the culture period T1 is 10-30 days, more preferably, 12-18 days;

[0051] Among them, in the mixed cell population containing nerve cells and astrocyte precursors, the proportion of nerve cells in the total number of cells is C1, and the proportion of astrocyte precursors in the total number of cells is C2, wherein C1:C2=(70%-98%):(1%-10%);

[0052] (3) digesting the mixed cell population in (1) to obtain a digested mixed cell population, wherein the digested mixed cell population comprises a single neural cell and a single astrocyte precursor in a suspended state;

[0053] (4) inoculating the digested mixed cell population in an uncoated culture medium in a culture system of a second culture medium, and adhering to the culture medium for a t2 time, so that the astrocyte precursors adhere to the culture medium, wherein t2 is 10-24 hours;

[0054] (5) separating the adherent astrocyte precursors from the suspended cells in the culture system, and washing the adherent astrocyte precursors in the culture medium to remove the residual suspended cells, thereby obtaining separated adherent astrocyte precursors, wherein the astrocyte precursors account for 70-95% of the total number of cells; and

[0055] (6) amplifying the isolated adherent astrocyte precursors obtained in the previous step to obtain stable and continuously passaged human astrocyte precursors.

[0056] In another preferred embodiment, the seeding density of the neural precursor cells is 1×10 3 -2×10 5 / cm 2 , preferably 5×10 3 -8×10 4 / cm 2 ; preferably 1×10 4 -2×10 4 / cm 2 .

[0057] In another preferred embodiment, the astrocyte precursor has one or more characteristics selected from the following group:

[0058] More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene S100β;

[0059] More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene NFIA.

[0060] In a fifth aspect of the present invention, a method for preparing astrocytes is provided, comprising the steps of:

[0061] (1) Providing an astrocyte precursor as described in the fourth aspect of the present invention;

[0062] (2) Cultivate the cells in (1) in a third culture medium for a culture time of T3 to obtain astrocytes.

[0063] (2) In a fourth culture medium, the cells in (1) are cultured in the coated culture medium for a culture time of T3 to obtain astrocytes.

[0064] In another preferred embodiment, the fourth culture medium is N2B27 culture medium without Vitamin A, which contains 5-25 ng / mL EGF, 5-25 ng / mL bFGF, and 10-30 ng / mL CNTF.

[0065] In another preferred embodiment, in (1), the density of astrocyte precursors is 1000-10000 / cm 2 ; preferably 2000-5000 / cm 2 .

[0066] In another preferred embodiment, in (2), the culture time T3 is 6-30 days, preferably 17-19 days, and more preferably 18 days.

[0067] In another preferred embodiment, the coated culture medium is a culture plate or dish coated with Matrigel.

[0068] In another preferred embodiment, the mature astrocytes have one or more characteristics selected from the following group:

[0069] More than 80%, preferably more than 90%, and most preferably more than 95% of the cells express the astrocyte maturation marker EAAT1;

[0070] More than 80%, preferably more than 90%, and most preferably more than 95% of the cells express the astrocyte maturation marker EAAT2.

[0071] In a sixth aspect of the present invention, an astrocyte is provided, wherein the astrocyte is prepared by the method described in the fifth aspect of the present invention.

[0072] In the seventh aspect of the present invention, there is provided a use of the astrocyte precursor as described in the fourth aspect of the present invention or the astrocyte as described in the fifth aspect of the present invention for preparing a pharmaceutical composition for preventing or treating diseases related to spinal cord injury (SCI).

[0073] In a ninth aspect of the present invention, a pharmaceutical composition is provided, comprising:

[0074] (1) an effective amount of the astrocyte precursor according to the fourth aspect of the present invention or the astrocyte according to the fifth aspect of the present invention; and

[0075] (2) A pharmaceutically acceptable carrier.

[0076] In another preferred embodiment, the dosage form of the pharmaceutical composition includes injection, lyophilized preparation, stem cell preparation, and cell model.

[0077] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 Figure A shows the flow chart of astrocyte precursor establishment. Figure B shows the bright field images during astrocyte establishment. Figure C shows the detection of astrocyte precursor marker genes NFIA and S100β during differentiation from day 0 to day 18 by RT-qPCR. Figure D shows the expression of GFAP and S100β identified by immunofluorescence staining on day 18.5. Figure E shows the statistical analysis of the ratio of GFAP and S100β in Figure D. Figure F shows the growth curve of astrocyte precursors. Figure G shows the identification of astrocyte precursors at the 10th generation by immunofluorescence staining of GFAP and S100β. Figure H shows the statistical analysis of the ratio of GFAP and S100β in astrocyte precursors at the 10th generation.

[0079] Figure 2Figure A shows the flow chart of the differentiation of astrocyte precursors into mature astrocytes. Figure B shows the expression changes of astrocyte-related genes from D0 to D18 analyzed by qPCR. Figure C shows the expression changes of GFAP and ALDH1L1 in astrocytes during the maturation process of D6, D12 and D18 identified by immunofluorescence staining. Figure D shows that astrocytes on the 18th day of differentiation express the mature markers EAAT1 and EAAT2. Figure E shows the statistical analysis of the proportion of EAAT1 and EAAT2 in astrocytes at the terminal differentiation day 18. Figure F shows that iNSC-differentiated astrocytes express HOXB4, a characteristic marker of the anterior position of the spinal cord. Figure G shows that mature astrocytes differentiated from hSCNPC express HOXC9, a characteristic marker of the posterior position of the spinal cord.

[0080] Figure 3 Figure A shows a schematic diagram of the differentiation of human anterior astrocyte precursor cells and mature astrocytes in the anterior part of the human brain from human neural precursor cells (iNSC) with the ability to differentiate into cortical neurons. Figure B shows the isolated astrocyte precursors, which express GFAP and S100β. Figures C and D show mature anterior astrocytes, identified by immunofluorescence staining, expressing EAAT 1 and EAAT2. DETAILED DESCRIPTION

[0081] After extensive and in-depth research, the inventor unexpectedly discovered a method for efficiently culturing astrocytes. Specifically, under conditions suitable for the growth of neurons and astrocyte precursors, the two cells are co-cultured. At D18-D18.5 days, through the difference in the adhesion performance of neurons and astrocyte precursors, cells with the morphology of astrocyte precursors that grow adherent to the wall are left, and the nerve cells that do not grow adherent to the wall or are not tightly attached to the wall are separated by blowing with a pipette, and finally the astrocyte precursors can be separated efficiently and non-destructively. And then used to obtain mature astrocytes. The method of the present invention is efficient, simple and rapid, and is conducive to establishing a differentiation system for directed differentiation from neural precursor cells to astrocytes. The present invention was completed on this basis.

[0082] the term

[0083] As used herein, the term "pluripotent stem cells (PSC)" refers to a type of cell that has both self-renewal and multidirectional differentiation potentials, including but not limited to: (1) embryonic pluripotent stem cells, and (2) pluripotent stem cells derived from somatic cell reprogramming.

[0084] As used herein, the term "induced pluripotent stem cells (iPSCs)" refers to a type of stem cell that has been transformed from somatic cells into a state of multipotential differentiation through a reprogramming process. Its multipotency is manifested in the ability to differentiate into three germ layers and multiple cell types.

[0085] As used herein, the term "differentiation" refers to the process by which stem cells transform into a target cell type in a specific context.

[0086] As used herein, the term "differentiation efficiency" refers to the frequency of transformation of pluripotent stem cells into target cell types in a specific context. For example, a differentiation efficiency of 90% means that at least 90% of the differentiated cell population is the target cell type.

[0087] Astrocytes, astrocytes

[0088] Astrocytes are the most common type of cells in the mammalian brain. These glial cells are star-shaped and have many long processes extending from the cell body. The processes contact nerve cells and play a role in supporting and separating nerve cells. Astrocytes play an important role in the formation, maintenance and function of synapses. Studies have shown that GFAP-positive astrocytes secrete a variety of guide molecules to guide the direction of axons in the corpus callosum and serve as a guide for neuronal position information during brain development. After astrocytes are produced, synapses between neurons begin to form with the help of astrocytes. Astrocytes play an important role in the transport of neurotransmitters. For example, astrocytes have glutamate receptors and glutamate transporters (EAAT1 and GLT-1) on their membranes to help transport and recycle glutamatergic neurotransmitters.

[0089] The differentiation products of astrocyte precursor cells are astrocytes, which provide nutrition and support for neurons.

[0090] Astrocytes are commonly cultured by isolating and filtering brain tissue for primary culture; with the development of human induced pluripotent stem cell (iPSC) technology, iPSCs are induced to differentiate in vitro to obtain astrocytes. In the prior art, the isolation and culture technology of astrocyte precursor cells is relatively complex, and the in vitro induction time is relatively long.

[0091] As used herein, "astrocytes of the present invention", "astrocyte population of the present invention" and "mature astrocytes of the present invention" are used interchangeably and refer to the cell population obtained by differentiation from astrocyte precursor cells as described in the fourth aspect of the present invention.

[0092] Preferably, the astrocytes of the present invention include brain astrocyte precursor cells (eg, astrocytes at the anterior end of the human brain) and spinal cord astrocytes (eg, astrocytes at the anterior end of the spinal cord and astrocytes at the posterior end of the spinal cord).

[0093] The culture method of the present invention provides an astrocyte precursor cell having strong proliferation ability and the ability to directionally differentiate into astrocytes, and a large number of high-purity astrocytes can be quickly obtained in a short period of time.

[0094] Preferably, the astrocyte precursor has one or more characteristics selected from the following group:

[0095] More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene S100β;

[0096] More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene NFIA.

[0097] Cultivation method of the present invention

[0098] In the present invention, neural precursor cells are cultured under conditions suitable for differentiation of neural cells and astrocyte precursors. The performance and characteristics of astrocyte precursors cultured under such in vitro conditions are more similar to those of naturally differentiated astrocyte precursors in vivo.

[0099] The method for culturing human astrocyte precursors of the present invention comprises: providing a mixed cell group comprising neural cells and human astrocyte precursors, and separating cells that do not grow adherently or are not tightly adherent to the wall (such as neurons or neural precursor cells) after adherent culture of the digested mixed cell group for t2 time to obtain human astrocyte precursors that grow tightly adherently to the wall; wherein t2 is 10-24h, preferably 11.5-12.5h, and more preferably 12h.

[0100] Here, precursor cells having the potential for human neural differentiation and human astrocyte precursor differentiation are used and cultured under conditions suitable for the precursor cells to differentiate into neural cells and human astrocyte precursors to obtain a mixed cell population containing neural cells and human astrocyte precursors.

[0101] It should be understood that the sources of the precursor cells in the present invention include, but are not limited to, human pluripotent stem cells (hPSC), human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC), neural stem cells (NSC), induced neural stem cells (iNSC), and human neural precursor cells; preferably, they can be human neural precursor cells, such as spinal cord neural precursor cells. Human neural precursor cells can be induced from human pluripotent stem cells using methods well known to the technicians of the present invention, and astrocyte precursors can be further obtained using the methods of the present invention.

[0102] Furthermore, a differentiation system for directed differentiation into spinal cord astrocytes can be established using the human spinal cord neural precursor cells of the present invention.

[0103] For example, a mixed cell population of neural cells and human astrocyte precursors is obtained by culturing in an astrocyte precursor induction medium (N2B27 without Vitamin A supplemented with NEAA and GlutaMAX) with the addition of 10 μM Y27632 for 10-30 days, preferably 18 days.

[0104] The mixed cell population of nerve cells and human astrocyte precursors is digested, and the nerve cells are removed by utilizing the difference in the adhesion ability of nerve cells and astrocyte precursors on the plate.

[0105] In a preferred embodiment, after 10-24h (more preferably 12h) of adherent culture, almost all of the astrocyte precursors grow in an adherent form, while the neurons grow in a non-adherent or loosely adherent form; further, the non-adherent cells can be removed by aspirating the culture medium; 1-2ml of astrocyte precursor screening culture medium is added, and the cells, neurons or neural precursor cells that are not tightly adherent in the culture medium are blown off; this process is repeated 2-3 times until only cells with astrocyte precursor morphology remain in the culture dish.

[0106] Furthermore, the obtained cells with astrocyte precursor morphology are subcultured to finally obtain astrocyte precursors that can be stably and continuously subcultured.

[0107] Furthermore, human astrocyte precursors can be further differentiated into mature astrocytes.

[0108] Preferably, the method of differentiating neural precursor cells into human astrocyte precursors of the present invention comprises the steps of:

[0109] (1) providing a mixed cell population containing neural cells and human astrocyte precursors;

[0110] (2) digesting the mixed cell population in (1), and then culturing the digested mixed cell population in an untreated cell culture dish culture system for t2 time to obtain an adherent culture mixed cell population, wherein the culture time t2 is 10-24 hours;

[0111] (3) Remove the culture medium containing non-adherent cells from the culture dish, use a pipette to draw fresh culture medium, and gently blow it into the culture dish to make the loosely adhered cells fall off the dish;

[0112] (4) performing the above method for multiple times, removing cells that are not attached to the wall or are not tightly attached to the wall from the mixed cell population that has been cultured by adherence, and obtaining cells that grow tightly attached to the wall, wherein the proportion of human astrocyte precursor cells in the total number of cells is 70-95%;

[0113] (5) Subculturing the cells that grow tightly adherently obtained in the above steps to obtain human astrocyte precursors that can be stably and continuously subcultured.

[0114] It should be understood that the conditions suitable for the differentiation of the precursor cells into neural cells and human astrocyte precursors include no additional addition of inductive or biased factors, such as no additional addition of cytokines that inhibit human neural differentiation, and / or cytokines that activate the differentiation of human astrocyte precursors, and simulating the process of spontaneous differentiation (e.g., only adding the Rock inhibitor Y27632 to prevent cell apoptosis).

[0115] Furthermore, the conditions suitable for the precursor cells to differentiate into neural cells and human astrocyte precursors may also include the addition of cytokines that inhibit human neural differentiation.

[0116] Among them, in the obtained mixed cell population containing neurons and human astrocyte precursors, the proportion of neurons in the total number of cells is C1, and the proportion of human astrocyte precursors in the total number of cells is C2, wherein C1:C2 = (70%-98%): (1%-10%); preferably C1:C2 = (40%-95%): (2%-18%); more preferably C1:C2 = (30%-90%): (3%-30%).

[0117] Pharmaceutical composition

[0118] The present invention provides a pharmaceutical composition containing the astrocyte precursor or astrocyte of the present invention.

[0119] The pharmaceutical composition of the present invention comprises a pharmaceutically acceptable carrier and an effective amount of active ingredients: the astrocyte precursor or astrocyte described in the present invention.

[0120] As used herein, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity on humans and / or animals and can be accepted by humans and / or animals.

[0121] As used herein, the components of a "pharmaceutically acceptable carrier" are substances that are suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), i.e., have a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.

[0122] The pharmaceutical composition of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the pharmaceutical preparation should match the mode of administration. The dosage form of the pharmaceutical composition of the present invention is an injection, a lyophilized preparation, a stem cell preparation, and a cell model. For example, it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition is preferably manufactured under sterile conditions.

[0123] The effective amount of the active ingredient of the present invention may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, the route of administration, etc. Generally, when the active ingredient of the present invention is administered at a dose of about 0.00001 mg-50 mg / kg animal body weight (preferably 0.0001 mg-10 mg / kg animal body weight) per day, a satisfactory effect can be obtained. For example, due to the urgency of the treatment condition, several divided doses may be administered per day, or the dose may be reduced proportionally. Generally, the pharmaceutical composition of the present invention can be administered by local injection or the like.

[0124] The pharmaceutically acceptable carriers of the present invention include (but are not limited to): water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.

[0125] The pharmaceutically acceptable carrier in the present invention can be a biocompatible carrier or a medically degradable tissue engineering carrier, including but not limited to: PCL, PGA, polyethylene glycol, hyaluronic acid, allogeneic bone repair materials, xenogeneic bone repair materials, gelatin, collagen, and silk. The motor neuron-like cell group or spinal cord-specific neural precursor cell in the present invention can be loaded on tissue engineering carriers of different sizes and shapes, and prepared into a biomaterial for treating a specific motor neuron-like cell group-related disease through in vitro pre-culture.

[0126] The main advantages of the present invention include

[0127] (1) Through the culture method of the present invention, a large number of astrocyte precursor cells can be obtained in vitro. The obtained astrocyte precursor cells have the ability to proliferate and differentiate into astrocytes, and high-purity astrocytes can be obtained in a short time.

[0128] (2) Through the method of culturing astrocytes of the present invention, mature astrocytes with good quality and high purity can be easily obtained after rapid culture for about 18 days; the culturing method of the present invention has the characteristics of low cost, high efficiency and strong operability.

[0129] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0130] The abbreviations involved in the present invention are as follows

[0131] Table 1

[0132] iPSC Induced Pluripotent Stem Cells hPSC Human pluripotent stem cells iNSC Induced neural stem cells hESC Human embryonic stem cells hSCNPC Human spinal cord neural precursor cells hNMPs Human neuromesoderm precursor cells SCI Spinal cord injury

[0133] Induction medium and culture medium formula:

[0134] hNMPs induction solution: bFGF (20 ng / ml), CHIR99021 (3 μM), SB431542 (10 μM), and Dorsomorphin (2 μM) were added to N2B27 without vitamin A.

[0135] hSCNPCs induction solution: bFGF (100 ng / ml), CHIR99021 (5 μM), SB431542 (10 μM), Dorsomorphin (2 μM), FGF8 (100 ng / ml), and compound E (200 nM) were added to N2B27 without vitamin A.

[0136] hSCNPC culture medium: 100 ml SCNPC culture medium, including 47 ml DMEM / F12 and 47 ml neurobasal culture medium (neural basal medium), plus 100X N2; 50X B27; 100X NEAA (non-essential amino acids); 100X GlutaMAX; 0.1mM 2-mercaptoethanol; 250nM Purmorphamine; 2μM SB431542; 3μM CHIR99021.

[0137] Astrocyte precursor induction medium (first culture medium): N2B27 culture medium without Vitamin A (containing a 1:1 mixture of DMEM / F12 and Neurobasal), with the addition of NEAA and GlutaMAX. 10 μM Y27632 can be added on the 1st to 2nd day to promote cell survival.

[0138] Astrocyte precursor screening culture medium (second culture medium): N2B27 culture medium without Vitamin A, supplemented with NEAA and GlutaMAX.

[0139] Astrocyte precursor expansion medium (third culture medium): N2B27 culture medium without Vitamin A supplemented with 20 ng / mL EGF, 20 ng / mL bFGF, NEAA, and GlutaMAX.

[0140] Astrocyte maturation culture medium (fourth culture medium): N2B27 culture medium without Vitamin A, supplemented with Gibico's NEAA, Gibico's Glutamax, 20 ng / mL EGF, 20 ng / mL bFGF, and 20 ng / mL CNTF.

[0141] Experimental methods:

[0142] (1) Method for efficiently differentiating human pluripotent stem cells into human neural mesodermal precursor cells

[0143] 1. Differentiation of human pluripotent stem cells into human neural mesodermal progenitor cells took four days. On day 0, 30 minutes before digestion of cells, Rock inhibitor Y27632 was added to the culture dish of human pluripotent stem cells at a final concentration of 10 μM. TM 1. Maintain and culture human pluripotent stem cells, remove the supernatant, add cell digestion solution, and digest at 37 degrees for 5-8 minutes to digest the cloned stem cells into single cells. Add mTeSR TM 1 Dilute the cell digestion solution and gently pipette the cells to make them uniform, transfer them to a centrifuge tube, and centrifuge at 800 rpm for 2 minutes.

[0144] 2. Aspirate the supernatant and add 1 ml of fresh mTeSR TM 1Resuspend the cells and count them.

[0145] 3. Human embryonic stem cells H9 were plated at a density of 400,000 cells per 3.5 cm culture dish. Different hiPSCs cell lines had different proliferation abilities and the initial differentiation density was appropriately explored and adjusted. The culture dish for cell plating was pre-coated with Matrigel at 37 degrees for 30 minutes. Cells were plated in mTeSR on days 0-1.TM 1. Culture in medium and add Rock inhibitor, Y27632, at a final concentration of 10 μM.

[0146] 4. On the first day, observe the cell adhesion. Aspirate the mTeSR TM 1. Replace the hNMPs induction solution.

[0147] 5. There is no need to change the culture medium on the second day.

[0148] 6. On the 3rd day, replace the hNMPs induction solution with fresh one.

[0149] 7. Differentiate into hNMPs on the 4th day.

[0150] (2) Method for differentiating human neural mesodermal precursor cells into human spinal cord neural precursor cell lines

[0151] Human pluripotent stem cells were differentiated for 4 days to obtain human neural mesodermal progenitor cells. Human neural progenitor cells were further induced for 6 days to form neural progenitor cells with a neural fate.

[0152] 1. On day 0, 30 minutes before digesting the cells, add the Rock inhibitor, Y27632, at a final concentration of 10 μM to the culture dish on day 4 of induction. The inventors then digested the hNMPs on day 4 of induction with cell digestion solution for 3-5 minutes to form single cells. Dilute the cell digestion solution with N2B27, and gently blow the cells evenly with a pipette, transfer them to a centrifuge tube, and centrifuge them at 1200 rpm for 2 minutes.

[0153] 2. Aspirate the supernatant, add 1 ml N2B27 to resuspend the cells and count them.

[0154] 3. Plate the cells at a high density of 3,000,000 per 3.5 cm dish in a dish pre-coated with Matrigel at 37°C for 30 minutes.

[0155] 4. Use hSCNPCs induction solution for differentiation, and add Rock inhibitor, Y27632, with a final concentration of 10 μM on day 0.

[0156] 5. During the following 6 days of differentiation, change the medium every day.

[0157] 6. On the 6th day of differentiation, the clones of neural progenitor cells induced by hNMPs were digested into single cells. Similarly, 30 minutes before digestion, the Rock inhibitor, Y27632, was added to the culture dish on the 6th day of differentiation at a final concentration of 10 μM. The single cells were resuspended in hSCNPCs culture medium, transferred to a centrifuge tube, and centrifuged at 1200 rpm for 2 minutes.

[0158] 7. Aspirate the supernatant, resuspend the cells in 1 ml hSCNPCs culture medium and count them.

[0159] 8. Cells were centrifuged at 330,000 / cm 2 The cells were plated at a density of 1.50 μg / cm2 on a culture dish pre-coated with Matrigel for 30 minutes at 37°C. hSCNPCs culture medium was added and Rock inhibitor, Y27632, was added at a final concentration of 10 μM.

[0160] According to the above method, high-purity spinal cord neural precursor cells (hSCNPC) can be obtained from human pluripotent stem cells in about 10 days, and experiments are carried out according to the method for culturing astrocytes of the present invention.

[0161] (3) Cryopreservation and thawing of human astrocyte precursors

[0162] 1. Aspirate the supernatant of astrocyte precursors, add Accutase, digest at 37 degrees for 3-5 minutes, add an equal volume of astrocyte precursor expansion culture medium to dilute Accutase, use a pipette to blow off the digested cells, collect them in a centrifuge tube, and centrifuge at 1200 rpm for 2 minutes.

[0163] 2. Take out the centrifuge tube from the centrifuge, remove the supernatant, add astrocyte expansion culture medium, and then slowly drop 10% DMSO to mix the cells thoroughly.

[0164] 3. Use a pipette to transfer the cells to cryopreservation tubes. The volume of cryopreservation solution in each cryopreservation tube should be 500-1000 μL.

[0165] 4. Place the cryovial in a cryopreservation box and store at -80 degrees overnight. The next day, transfer to liquid nitrogen for storage.

[0166] 5. When reviving astrocyte precursors, take out the cells from liquid nitrogen and shake them quickly in a 42-degree water bath to melt the ice in the cryotube.

[0167] 6. Use a pipette to aspirate the cryopreservation solution and add it to 5-8 mL of astrocyte expansion culture medium preheated in a 37-degree incubator. Centrifuge at 1200 rpm for 2-3 minutes.

[0168] 7. Remove the centrifuge tube, aspirate the supernatant, add fresh astrocyte expansion medium to resuspend the cells, and revive them in a culture dish pre-coated with Matrigel according to the freezing density.

[0169] Example 1 Highly efficient differentiation of human neural precursor cells into human astrocyte precursors

[0170] 1. On D0, remove the supernatant of neural progenitor cells, add Accutase, and digest in a 37-degree incubator for 3-5 minutes to digest the neural progenitor cells into single cells. Add an equal volume of N2B27 to dilute Accutase, and add Rock inhibitor, Y27632, at a final concentration of 10 μM. Use a pipette to gently blow and mix the cells thoroughly, transfer to a centrifuge tube, and centrifuge at 1200 rpm for 2 minutes.

[0171] 2. After centrifugation, remove the supernatant from the centrifuge tube, add fresh astrocyte precursor induction culture medium and 10 μM Y27632. Mix thoroughly and resuspend the cells. Count.

[0172] 3. Human neural progenitor cells were cultured at 20,000 / cm 2 Inoculate the cells into a cell adherent culture dish coated with Matrigel at 37 degrees in advance. The inoculation density can be adjusted appropriately according to the different proliferation abilities of different human neural progenitor cells. Add astrocyte precursor induction culture medium and 10 μM Y27632.

[0173] 4. Culture in a 37-degree cell culture incubator and change the culture medium every other day. As the cell density increases, fresh culture medium can be replaced every day from D9 to D18 to maintain adequate nutrition.

[0174] 5. On D18, add Accutase and fully digest at 37 degrees for 8-10 minutes to digest the differentiated cells. Add an equal volume of fresh N2B27 and gently blow with a pipette to fully blow off the cells on the culture dish. Collect them in a centrifuge tube and centrifuge at 1200 rpm for 2 minutes.

[0175] 6. Remove the supernatant and add the cells with astrocyte precursor screening culture medium to inoculate them in a non-coated adherent culture dish at a ratio of 2:1. Observe the adherent astrocyte precursors under a microscope after 12 hours, remove the culture medium and non-adherent cells. Add 1-2 ml of astrocyte precursor screening culture medium and gently blow off the neurons or neural precursor cells in the culture dish; repeat 2-3 times until only cells with astrocyte precursor morphology remain in the culture dish.

[0176] 7. Then remove the supernatant from the culture dish and add astrocyte precursor expansion medium. Replace the astrocyte expansion medium every other day until the cells fill the culture dish.

[0177] 8. Add Accutase to digest for 3-5 minutes, add an equal volume of astrocyte expansion medium to dilute, use a pipette to fully disperse the cells, count, and use 20,000 / cm 2 The cells were seeded at a density of 100 μg / mL in a culture dish pre-coated with Matrigel and passaged.

[0178] 9. Astrocyte precursors can be serially passaged.

[0179] Experimental results: The establishment process of astrocyte precursors and the astrocyte precursors obtained Figure 1 As shown. Among them, at D18.5, about 78% of the cells in the astrocyte precursors expressed the astrocyte precursor marker gene S100β, and about 80% of the cells expressed the astrocyte precursor marker gene NFIA. That is, the purity of the astrocyte precursors was about 70-80%.

[0180] Furthermore, the culture time of the mixed population was shortened to 12 days, and astrocyte precursors could be isolated from the mixed cell population in 12.5 days.

[0181] Example 2 Method for terminal differentiation into mature astrocytes

[0182] 1. Aspirate the supernatant, add Accutase to the astrocyte precursors and digest at 37 degrees for 3-5 minutes. Add an equal volume of N2B27 culture medium to dilute, blow off the cells thoroughly, collect them in a centrifuge tube, and centrifuge at 1200rpm for 2-3 minutes.

[0183] 2. Aspirate the supernatant in the centrifuge tube, add astrocyte maturation culture medium, resuspend the cells, and count.

[0184] 3.3300 / cm 2 The cells were seeded at a density of 1.54 μg / mL in a culture dish pre-coated with Matrigel, and astrocyte maturation culture medium was added.

[0185] 4. Change the medium every other day. After 18 days of culture, astrocytes will gradually mature.

[0186] Experimental results: The flow chart of astrocyte precursor differentiation into mature astrocytes is as follows Figure 2 As shown in A. At D18, about 95% of the mature astrocytes obtained expressed the astrocyte maturation marker EAAT1, and about 95% of the cells expressed the astrocyte maturation marker EAAT2, that is, the purity of the obtained astrocytes was about 95%.

[0187] Example 3 Astrocyte precursors or mature astrocytes differentiated from other precursor cells

[0188] Similarly, according to the methods of Examples 1 and 3 of the present invention, other precursor cells (such as induced neural stem cells iNSC) can also be used to obtain astrocyte precursors and mature astrocytes (such as Figure 3 shown).

[0189] discuss:

[0190] In the process of human pluripotent stem cells differentiating quickly into astrocytes without neural differentiation, it is usually necessary to edit the genes of the cells and overexpress transcription factors related to astrocyte fate determination (such as NF1A). However, this method interferes with the genome of the cells and is not suitable for clinical transformation. Traditional astrocyte differentiation starts from human pluripotent stem cells and usually goes through the neuroepithelial cell differentiation stage. This process inevitably produces neurons, and it usually takes more than 100 days to obtain astrocytes.

[0191] The precursor cells of the present invention can be precursor cells with human neural differentiation and human astrocyte precursor differentiation potential, such as pluripotent stem cells (such as ESC, iPSC, or neural stem cell NSC); or neural precursor cells, such as those from spinal cord neural precursor cell populations, and then cultured to obtain spinal cord astrocytes.

[0192] At present, the differentiation time of human spinal cord astrocytes is relatively long, and there are few studies on directional differentiation. Most methods can only differentiate into astrocytes at the front end of the spinal cord. Since the role of spinal cord astrocytes in disease models or cell therapy needs to be further studied, it is of great significance to establish a differentiation system for directional differentiation of human spinal cord neural precursor cells into spinal cord astrocytes.

[0193] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for preparing a mixed cell population of neural cells and astrocyte precursors, characterized in that: Includes steps: (1) providing a precursor cell; and (2) culturing the precursor cells in the coated culture medium for a period of time T1 under conditions suitable for differentiation of the precursor cells into neural cells and astrocyte precursors, thereby obtaining a mixed cell population containing neural cells and astrocyte precursors, wherein the culture period T1 is 8-30 days, In a mixed cell population containing neurons and astrocyte precursors, the proportion of neurons in the total number of cells is C1, and the proportion of astrocyte precursors in the total number of cells is C2, wherein C1:C2=(70%-98%):(1%-10%).

2. A method for culturing astrocyte precursors, characterized in that: Includes steps: (1) providing a mixed cell population containing neural cells and astrocyte precursors; (2) digesting the mixed cell population in (1) to obtain a digested mixed cell population, wherein the digested mixed cell population comprises a single neural cell and a single astrocyte precursor in a suspended state; (3) inoculating the digested mixed cell population in an uncoated culture medium in a culture system of a second culture medium, and adhering to the culture medium for a t2 time, so that the astrocyte precursors adhere to the culture medium, wherein t2 is 10-24 hours; (4) separating the adherent astrocyte precursors from the suspended cells in the culture system, and washing the adherent astrocyte precursors in the culture medium to remove the residual suspended cells, thereby obtaining separated adherent astrocyte precursors, wherein the astrocyte precursors account for 70-95% of the total number of cells; and (5) The adherent astrocyte precursors separated in the previous step are expanded and cultured to obtain human astrocyte precursors that are stably and continuously passaged.

3. A method for isolating astrocyte precursors from a mixed cell population containing neural cells and astrocyte precursors, characterized in that: Includes steps: (1) providing a mixed cell population containing neural cells and astrocyte precursors; (2) digesting the mixed cell population in (1) to obtain a digested mixed cell population, wherein the digested mixed cell population comprises a single neural cell and a single astrocyte precursor in a suspended state; (3) inoculating the digested mixed cell population in an uncoated culture medium in a culture system of a second culture medium, and adhering to the culture medium for a t2 time, so that the astrocyte precursors adhere to the culture medium, wherein t2 is 10-24 hours; and (4) Separating the adherent astrocyte precursors from the suspended cells in the culture system, and washing the adherent astrocyte precursors in the culture medium to remove the residual suspended cells, thereby obtaining separated adherent astrocyte precursors, wherein the astrocyte precursors account for 70-95% of the total number of cells.

4. An astrocyte precursor, characterized in that: The astrocyte precursors are prepared by the following method: (1) Providing a precursor cell; (2) culturing human neural progenitor cells in a culture system containing a first culture medium containing 6-12 μM ROCK inhibitor, and culturing in the coated culture medium for a period of time T1, thereby obtaining a mixed cell population containing neural cell and astrocyte precursors, wherein the culture period T1 is 10-30 days, more preferably, 12-18 days; Among them, in the mixed cell population containing nerve cells and astrocyte precursors, the proportion of nerve cells in the total number of cells is C1, and the proportion of astrocyte precursors in the total number of cells is C2, wherein C1:C2=(70%-98%):(1%-10%); (3) digesting the mixed cell population in (1) to obtain a digested mixed cell population, wherein the digested mixed cell population comprises a single neural cell and a single astrocyte precursor in a suspended state; (4) inoculating the digested mixed cell population in an uncoated culture medium in a culture system of a second culture medium, and adhering to the culture medium for a t2 time, so that the astrocyte precursors adhere to the culture medium, wherein t2 is 10-24 hours; (5) separating the adherent astrocyte precursors from the suspended cells in the culture system, washing the adherent astrocyte precursors in the culture medium, removing the residual suspended cells, and obtaining separated adherent astrocyte precursors, wherein the astrocyte precursors account for 70-95% of the total number of cells; and (6) amplifying the isolated adherent astrocyte precursors obtained in the previous step to obtain stable and continuously passaged human astrocyte precursors.

5. The astrocyte precursor according to claim 4, characterized in that (4), wherein the isolated adherent astrocyte precursors have one or more characteristics selected from the group consisting of: More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene S100β; More than 70%, preferably more than 75%, and most preferably more than 85% of the cells express the astrocyte precursor marker gene NFIA.

6. A method for preparing astrocytes, characterized in that: Includes steps: (1) Providing an astrocyte precursor as described in claim 4; (2) Cultivate the cells in (1) in a third culture medium for a culture time of T3 to obtain astrocytes. (2) In a fourth culture medium, the cells in (1) are cultured in the coated culture medium for a culture time of T3 to obtain astrocytes.

7. An astrocyte, characterized in that: The astrocytes are prepared by the method according to claim 6.

8. Use of the astrocyte precursor according to claim 4 or the astrocyte according to claim 7, characterized in that: The invention is used for preparing a pharmaceutical composition for preventing or treating diseases related to spinal cord injury (SCI).

9. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: (1) an effective amount of the astrocyte precursor according to claim 4 or the astrocyte according to claim 7; and (2) A pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to claim 9, characterized in that The dosage forms of the pharmaceutical composition include injections, freeze-dried preparations, stem cell preparations, and cell models.